Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Seborrheic dermatitis improved after a hair transplant. Effective treatments include Sebamed Anti-Dandruff Shampoo, Vichy Anti-Dandruff Shampoo, Nizoral, and medications like finasteride, dutasteride, and minoxidil.

Essential oils like rosemary, thyme, lavender, and cedar wood in a carrier oil may effectively treat alopecia areata and potentially male pattern baldness by stimulating the scalp similarly to minoxidil. The user plans to try this routine and share results.

A user is trying fluridil/topilutamide for hair loss and experiencing side effects like pain in the testicles and genital discomfort. They previously had adverse effects with finasteride, dutasteride, and RU58841, and are considering other treatments like topical dutasteride and spironolactone for maintenance before a hair transplant.

A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

The user is seeking advice on hair loss treatment after three months on finasteride, having stopped minoxidil due to a rash, and is now using nanoxidil. Suggestions include switching to oral minoxidil, adding dutasteride, and incorporating microneedling for better results.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

The conversation discusses hair loss treatments, specifically using a Dermaroller, Minoxidil, and RU58841 for two months. The user shared progress pictures showing the results of these treatments.

Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation discusses hair loss treatments, specifically the use of topical minoxidil and derma-stamping, with suggestions to add finasteride or dutasteride for better long-term results. Ketoconazole shampoo is also considered for scalp health.

A 35-year-old man has been using a topical solution with finasteride, minoxidil, retinoic acid, and hydrocortisone for hair regrowth, experiencing minor side effects. He plans to remove hydrocortisone due to potential long-term health risks.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

The user is using Keeps Topical Minoxidil and Finasteride foam, along with derma stamping and pumpkin seed oil pills, to address hair loss. They report no significant side effects and observe new hair growth, while discussing the pros and cons of topical versus oral treatments.

The user has been using RU58841 with minoxidil for hair loss, which helped but caused itchiness, and is considering increasing the dose and adding topical finasteride to the treatment. They are inquiring if they can mix RU58841 and finasteride into one solution with Stemoxydine or if they need separate solutions and which to apply first.

The conversation is about the effectiveness and safety of a hair loss treatment called Pyri, with users discussing its availability and comparing it to other treatments like RU58841, fluridil, and alfatradiol. Some users are waiting for FDA approval before using Pyri, while others share their positive experiences with RU58841 and suggest additional treatments with minimal side effects.

The individual has been using minoxidil for beard growth for over two years, started oral minoxidil and dutasteride six months ago, and began RU58841 three months ago, which significantly enhanced their results. They are open to answering questions about their hair loss treatment experience.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A user noticed hair loss since age 16 and is now using minoxidil 5% twice daily, scalp massages, and a derma stamp weekly, along with Alpecin Caffeine Shampoo. They report seeing new hair growth and are happy with the progress.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

A 29-year-old male experienced hair regrowth using minoxidil 5% foam and KX826 after stopping finasteride due to side effects. He applies both treatments once daily and reports no side effects from the current regimen.

Switching from oral to topical dutasteride can cause shedding due to changes in DHT levels, and it's recommended to overlap both treatments to minimize this effect. Topical dutasteride may cause scalp irritation, and the user is considering dutasteride mesotherapy as an alternative.

Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.

Minoxidil can cause facial bloat, which some users manage by adjusting sodium intake or using it only on the scalp. Alternatives like finasteride or dutasteride are suggested for those concerned about facial changes.

The user has been using Roman 3-in-1 topical treatment (finasteride 0.3%, minoxidil 6%, tretinoin 0.025%) and a 0.25 mm dermaroller for four months to address crown thinning. They are seeking advice on whether to continue with the current regimen, switch to oral finasteride, or try dutasteride for better results.

The user experienced reduced hair shedding after three months of injecting 1mg BPC-157 into the scalp, while continuing to use dutasteride and minoxidil. The injections are painful, and the user sometimes switches to injecting into the buttocks.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.